Evidence map›Paper›PMID 42137298›Full record

ArticleMolecular therapy. Advances2026

Productivity and genetic stability of a novel baculovirus vector for multigene expression from independent transgene loci.

Linda A de Jong, Mels Schrama, Jelmer Willems, Adriaan H de Wilde, Corinne Geertsema, Marleen Henkens, Dirk E Martens, Barbara P Sanders, Monique M van Oers, Gorben P Pijlman

Abstract read
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Linda A de JongLaboratory of Virology, Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands.
Mels SchramaDepartment of Bioprocess Engineering, Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands.
Jelmer WillemsVectorY Therapeutics, Science Park 408, 1098 XH Amsterdam, the Netherlands.
Adriaan H de WildeVectorY Therapeutics, Science Park 408, 1098 XH Amsterdam, the Netherlands.
Corinne GeertsemaLaboratory of Virology, Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands.
Marleen HenkensLaboratory of Virology, Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands.
Dirk E MartensDepartment of Bioprocess Engineering, Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands.
Barbara P SandersVectorY Therapeutics, Science Park 408, 1098 XH Amsterdam, the Netherlands.
Monique M van OersLaboratory of Virology, Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands.
Gorben P PijlmanLaboratory of Virology, Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The baculovirus expression vector system is an established platform for large-scale production of (glyco)proteins, subunit vaccines, virus-like particles, and recombinant adeno-associated virus (rAAV) vectors. We engineered a novel bacmid vector (BAC6) to improve genetic stability by deletion of the non-homologous repeat (hr) origin of DNA replication (ori) and to preserve product integrity and recovery through deletion of chitinase and cathepsin. Tn7-based transposition in

Indexed as

AAVadeno-associated virusbacmidbaculovirus expression vector systemgenome editingillumina next generation sequencingSARS-CoV-2

Identifiers

PMID42137298
PMCPMC13148896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.